GLP-1 miligaramu 10

▎ GLP-1 ka baarakɛcogo

▎ GLP-1 Sɛgɛsɛgɛli

GLP-1 ka ɲininiw kɛcogo ye mun ye?

GLP-1 ye hadamaden ka glucagon-like peptide-1 (GLP-1) analogue ye, a bɛ jate GLP-1 minɛbaga agoniste ye. GLP-1 ye ɔrimɔni ye min bɛ bɔ banakɔtaa la dumuni kɛlen kɔfɛ. A jɔyɔrɔ ka bon inisɔndiya bɔli la ani ka sukaro bɔli bali, o la a bɛ joli sukaro hakɛ labɛn. GLP-1 yiriwali bɔra GLP-1 farikolo baarakɛcogo ɲinini kuncɛlenw na. Nka, GLP-1 tilancɛ si hakɛ ka surun kosɛbɛ farikolo la, a bɛ miniti 1 fo miniti 2 ɲɔgɔn dɔrɔn de kɛ, o sababu bɛ bɔ a la ko a ka teli ka tiɲɛ dipeptidil peptidase-4 (DPP-4) enzymes fɛ farikolo la. Walasa ka se sɔrɔ o dantigɛli kan, dɔnnikɛlaw ye GLP-1 jɔcogo sɛmɛntiya ni amino acide kɛrɛnkɛrɛnnenw caman cili ye ani ka a tangalan kuluw fara a kan, ka dɔ fara a ka se ka DPP-4 anzimuw kɛlɛ, o la, a ka baara ^janya kuntaala GLP-1 jɔcogo la, alanini min bɛ jɔyɔrɔ 8nan na, o bɛ bila asidi α-aminoisobutyric (Aib) nɔ na. O fɛn caman Changement in tɛ fura sabatili dɔrɔn ɲɛ, nka a bɛ a sirili barika bonya fana GLP-1 minɛbaga la (Ma H, 2020). fara o kan, asidi tuluma kɛrɛfɛ cakɛda kɛrɛnkɛrɛnnen dɔ min sirilen don a C-terminus la, min sirilen don γ-glutamine fɛ ni lisini tolenw ye, o bɛ a tilancɛ janya ka taa a fɛ, o bɛ kɛ sababu ye ka pikiri kɛ siɲɛ kelen dɔgɔkun kɔnɔ walima siɲɛ kelen don o don da ^la Ka A daminɛ na, a sinsinnen bɛ GLP-1 nafama ɲininiw ni a caman cili kan, GLP-1 laɲini ye ka furakɛli suguya ɲumanw di sukarodunbana suguya 2 banabagatɔw ma ^{[1, 2]} . Jatebɔcogo ɲuman kɔfɛ, a bɛ GLP-1 farikolo baara mara ka sɔrɔ a bɛ a ka furakɛlicogo ɲɛ kosɛbɛ, ka kɛ GLP-1 minɛbaga agoniste nafama ye min bɛ baara kɛ waati jan kɔnɔ. GLP-1 ɲinini ni a labɛnni nafa ka bon kosɛbɛ sukarodunbana suguya 2 furakɛli la, o bɛ sugandili kura di banabagatɔw ma. Ni a bɛ a jɔcogo ɲuman kɛ, a bɛ se sɔrɔ GLP-1 nafama tilancɛ waati surun gɛlɛya kan, ka fura in sabatili n’a baara kuntaala bonya.

GLP-1 ka baarakɛcogo ye mun ye?

GLP-1 ye glucagon-like peptide-1 (GLP-1) minɛbaga agoniste ye min bɛ baara kɛ waati jan kɔnɔ, wa a kɛcogo ye nin ye:

Joli sukaro hakɛ jateminɛni : I n’a fɔ pepitiri-1 minɛbaga kura min bɛ i n’a fɔ sukaro (GLP-1RA), GLP-1 bɛ dɔ bɔ banabagatɔw ka dumuni nege la kosɛbɛ ani ka dɔ bɔ u ka dumuni tulumafɛnw diyabɔli la, a kɛtɔ ka dumuni nege bali. A bɛ baloyɔrɔ labɛn hipotalamus kɔnɔ, ka dumuni dunta dɔgɔya, ka dɔ fara fasa kan, ka kɔnɔbara lankolonya bali, ka kɔnɔbara lamagacogo dɔgɔya, o la, a bɛ se ka kɛ sababu ye ka mɔgɔ girinya dɔgɔya. Kisɛya bɛ dɛmɛ ka inisɔndiya sabati ani ka joli sukaro hakɛ labɛn ka taa a fɛ ^[3] (Kim HS, 2021). GLP-1 bɛ girinya dɔgɔya sosow la ni senfagabana siraw jɛnsɛnnenw ye. Kɔlɔsiliw y’a jira ko GLP-1 bɛ baara kɛ yɔrɔw la k’a ɲɛsin u ma i n’a fɔ kunsɛmɛnasumaya, septal nucléaire ani hypothalamus. Hali n’a tɛ joli ni kunsɛmɛ sira tigɛ, a bɛ ɲɔgɔn sɔrɔ ni kunsɛmɛ ye kɔnɔbara lamini yɔrɔw fɛ ani yɔrɔ kɛrɛnkɛrɛnnenw fɛ minnu bɛ kɔnɔbara kɛrɛfɛ. A bɛ c-Fos cɛmancɛ baara bila kunsɛmɛ yɔrɔ 10 la, o la, kɔfɛla yɔrɔ minnu laɲininen don GLP-1 fɛ ani yɔrɔ filanan minnu tɛ GLP-1R jɛɲɔgɔnya tilennen sɔrɔ, i n’a fɔ kɛrɛfɛla parabrachial nucleus. Sɛgɛsɛgɛli otomatiki b’a jira ko baarakɛcogo bɛ se ka kɛ dumuniw dabila ye minnu bɛ kɔlɔsi senfagabana fɛ minnu bɛ parabrachial nucleus laterale kɔnɔ, o bɛ joli sukaro hakɛ ^labɛn.

Kɔnɔnatumuw labɛncogo : GLP-1 bɛ baara kɛ GLP-1 minɛbagaw kan kɔnɔbara basigilen na. Vagus nerve ka afferent sira fɛ, a bɛ baara kɛ yɔrɔw la minnu bɛ sugunɛ na i n’a fɔ a kelen-kelen bɛɛ ka nucléaire ani vagus nerve dorsal motor nucleus walasa ka kɔnɔbara lamagacogo ɲɛnabɔ. A bɛ se ka kɔnɔbara basigilen sɔgɔsɔgɔli bali, ka pyloric sphincter (piloric sphincter) tansiyɔn bonya, ka dumuni sigi waati janya kɔnɔbara la, ka a donni bila kɔfɛ kɔnɔbara la, ka dumuni kɔfɛ joli sukaro jiginni teliya bali ani ka joli sukaro caman cili sabati ^[5] (Katsurada K, 2016). Ka fara o kan, GLP-1 bɛ baara kɛ GLP-1 minɛbagaw kan farikolo cɛmancɛ la, kɛrɛnkɛrɛnnenya la yɔrɔw la i n’a fɔ nucleus arcuate ani nucléaire paraventriculaire de la hypothalamus. A bɛ dumuni nege bilali fɛnw bɔli bali i n’a fɔ neuropeptide Y (NPY) ani agouti-related protein (AgRP), ani o waati kelen na, a bɛ pro-opiomelanocortin (POMC) senfagabana baara, ka α-melanocyte-stimulating hormone (α-MSH) ^sabati bɔli O nɔ ninnu bɛ fasa dusukunnata lase mɔgɔ ma, ka kɔngɔ dɔgɔya, ka dumuni dunta dɔgɔya, o bɛ nɔ ɲuman bila joli sukaro kɔlɔsili la cogo la min tɛ ɲɛ.

Dusukun ni jolisiraw lakanani : GLP-1 bɛ se ka joli siraw kɔnɔnatumuw dɛmɛ u ka joli siraw bonya fɛnw bɔ i n’a fɔ ɔkisidi azotiki (NO), ka joli siraw bonya seko bonya ani ka joli bolicogo ɲɛ. O waati kelen na, a bɛ funu jaabiw ni oksidan degunw bali, ka joli siraw kɔnɔnatumuw tiɲɛni dɔgɔya, ka joli siraw gɛlɛya dɔgɔya. Ka fara o kan, ni a bɛ dumuni nege ni dumuni dunta dɔgɔya, GLP-1 bɛ dɛmɛ don farikolo girinya dɔgɔyali la, ka sukarodunbanaw ɲɛ, ka triglycérides ni low-density lipoprotein cholesterol (LDL-C) hakɛ dɔgɔya, ani ka dɔ fara lipoprotéine cholesterol (HDL-C) hakɛ kan. A bɛ se ka nɔ ɲuman bila tansiyɔn na fana ni a sugunɛbilenni ni farikolojidɛsɛ baarakɛcogo ɲɛnabɔ, ka tansiyɔn jiginni ni dusukunnabana faratiw dɔgɔya ^bɛ .

GLP-1 ani WAT jiginni ka kɛ BAT ye ani BAT baarakɛcogo sɛbɛnniko ɲɛnabɔli.

Soso: PubMed ^{[12] Ɲɛjirali dɔw.}

Kɔrɔbɔli ni kalan kunbabaw ye jumɛnw ye?

Furakɛcogo ni a kɛcogo ɲuman : Ni GLP-1 dilanni kɛra, fɛɛrɛ dɔ kɛra min bɛ se ka a siri albumini na min bɛ se ka wuli ka bɔ a nɔ na walasa ka fura in ka baara kɛ waati janya. Ni asidi fatɔw ni ɲɔgɔndan ɲumanw faralen don ɲɔgɔn kan cogo ɲuman na, ka sɔrɔ ka GLP-1 minɛbaga (GLP-1R) ka baarakɛcogo sabati, a sirili se min bɛ kɛ ni albumini ye, o cayara ^kosɛbɛ.

Fura tali : GLP-1 ye pepitiri-1 minɛbaga ye min bɛ i n’a fɔ glucagon (GLP-1 RA) ni a bɔli tilancɛ janya bɛ se ka kɛ, o bɛ a to a bɛ se ka pikiri kɛ farikolo jukɔrɔ siɲɛ kelen dɔgɔkun kɔnɔ. Sukarodunbana suguya 2 (T2DM) bɛ banabagatɔ minnu na, GLP-1 pikiri kɛli farikolo jukɔrɔ siɲɛ kelen dɔgɔkun kɔnɔ, o girinya dɔgɔyali nɔ ka fisa ni GLP-1RA tɔw ta ye siɲɛ kelen dɔgɔkun kɔnɔ. Fasa II tata hakɛ ɲinini sɛgɛsɛgɛli la banabagatɔ fasalenw kan minnu tɛ T2DM sɔrɔ, GLP-1 pikiri kɛli farikolo jukɔrɔ siɲɛ kelen don o don, o ye girinya dɔgɔyali nɔ ɲuman jira ka tɛmɛ furakisɛ ni liraglutide miligaramu 3,0 kan siɲɛ kelen don o don. GLP-1 ka girinya dɔgɔyali hakɛ min bɛ sɔrɔ nin ɲinini in na, o tɛmɛna sariyaw kan minnu sigilen don farikolojidɛsɛ furaw kan Erɔpu furakɛlitɔn (EMA) ani Ameriki dumuniko ni furako ɲɛmɔgɔso (FDA) fɛ, wa a farati tɛ, o b’a jira ko GLP-1 pikiri kɛli farikolo jukɔrɔ siɲɛ kelen don o don, o bɛ se ka kɛ farikolojidɛsɛ fura ye ^sini.

Dusukun ni jolisiraw banaw furakɛli ni dusukun baarakɛcogo ɲɛnabɔli ye : STEP-HFpEF sɛgɛsɛgɛli jaabiw y’a jira ko sukarodunbanakisɛfagalan furakisɛ 1 agoniste GLP-1 hakɛ caman ta ye dusukun tantanni taamasiɲɛw ɲɛ kosɛbɛ ni ejection fraction préservée (HFpEF) ye ani ka N-terminal pro-B-type natriuretic peptide hakɛ dɔgɔya (NT-proBNP) (NT-proBNP) ye. Sɛgɛsɛgɛliw y’a jira ko furakɛli jugumanba ni GLP-1 ye, o bɛ se ka dɔ fara hadamadenw ka ɲɛgɛnɛsiraw tansiyɔn kan ka tɛmɛ siɲɛ saba kan cogo la min bɛ bɔ a tata hakɛ la, k’a sɔrɔ a ma kɛ sababu ye ka dɔ fara farikolojidɛsɛ kan. O nɔ in bɛ se ka kɛ sababu ye ka dɔ fara Ca2+ tali kan sarcoplasmic reticulum fɛ. GLP-1 tata hakɛ caman furakɛli dusukun tantanni banabagatɔw la, o bɛ se ka dusukun tantanni baara ɲɛ, o la, a taamasiɲɛw bɛ nɔgɔya ^{[9] .}.

GLP-1 bɛ sɛgɛsɛgɛli la sugunɛbilenni min tɛ dɔlɔ ye (NASH) furakɛli la: GLP-1 dilanni hakilitigi ye dɛmɛba don joli sukaro kɔlɔsili la, farikolo girinya, tansiyɔn, joli tulumafɛnw, β-cell baara, ani dusukun ni jolisiraw la sukarodunbana suguya 2 bɛ banabagatɔ minnu na. Ka fara o kan, GLP-1 furakɛcogo da la, o bɛ se ka nafa wɛrɛ lase banabagatɔw ka furakɛli labatoli siratigɛ la ^[7]..

Danfara jumɛnw bɛ GLP-1 ka girinya dɔgɔyali nɔw la jamanaden danfaralenw ni ɲɔgɔn cɛ?

Baliku minnu ka dusukunnabana tun bɛ u la ka kɔrɔ, minnu girinya ka ca walima minnu fasalen don nka sukarodunbana tɛ u la: SELECT dusukun ni jolisiraw kɔlɔlɔw sɛgɛsɛgɛli la, GLP-1 ye dusukun ni jolisiraw kɔlɔlɔbaw dɔgɔya ni 20% ye baliku 17604 la minnu ka dusukunnabana tun bɛ u la ka kɔrɔ, minnu girinya ka ca walima minnu fasalen don, ani minnu tɛ sukarodunbana sɔrɔ ^[10] (Ryan DH, 2024). Nin sɛgɛsɛgɛli in kɔnɔ min tun ɲɛfɔra ka kɔn, ɲininikɛlaw ye GLP-1 nɔw sɛgɛsɛgɛ farikolo girinya kan, farikolo jateminɛ kɔlɔlɔw la, lakana kan, ani muɲuli la ka kɛɲɛ ni farikolo girinya hakɛ (IMC) daminɛ ye. Banabagatɔ minnu bɛ GLP-1 ta, olu farikolo girinya bɛ dɔgɔya ka taa a fɛ dɔgɔkun 65 kɔnɔ, o bɛ mɛn fo san 4. Dɔgɔkun 208 la, ni i ye a suma ni furakisɛ kulu ye, GLP-1 kɛra sababu ye ka farikolo girinya hakɛ caya (-10,2%), cɛmancɛ lamini (santimɛtɛrɛ -7,7), ani cɛmancɛ ni cɛmancɛ hakɛ (-6,9%), ka sɔrɔ furakisɛ kulu ta la, dɔ bɔra (-1,5%, -1,3 santimɛtɛrɛ, ani -1,0%) la, wa ni u ni furakisɛ ta kɛra ɲɔgɔn fɛ, olu bɛɛ kɛra jateminɛ nafama ye. Kisɛya dɔgɔyali min kɔrɔ ye kɛnɛyako ta fan fɛ, o kɛra cɛw ni musow bɛɛ la, siyaw bɛɛ la, farikolo suguyaw bɛɛ la, ani maraw bɛɛ la. GLP-1 tun bɛ tali kɛ kɔlɔlɔ jugumanw dɔgɔyali la. BMI suguya kelen-kelen bɛɛ la (<30, 30 ka se <35, 35 ka se <40 ma, ani ≥40 kg/m²), GLP-1 kɔlɔlɔ jugumanw sɔrɔli (ko minnu kɔlɔsira mɔgɔ-san 100 kɔnɔ) olu hakɛ tun ka dɔgɔn (43,23, 43,54, 51,07, ani 47,06 GLP-1, ani 50,48, 49,66, 52,73, ani 60,85 ye furakisɛ tali la). GLP-1 tun bɛ tali kɛ kɔrɔbɔli fura tali dabila hakɛ caya la. Ni IMC suguya dɔgɔyara, a tali dabila hakɛ cayara. SELECT sɛgɛsɛgɛli la, dɔgɔkun 208 kɔnɔ, GLP-1 ye farikolo girinya dɔgɔyaliba lase kɛnɛyaso la ani ka ɲɛtaa kɛ farikolojidɛsɛ hakɛw la ni a ni furakisɛ ta kɛra ɲɔgɔn fɛ, wa o girinya dɔgɔyali tora sen na san 4 kɔnɔ.

Mɔgɔ minnu fasalen don walima minnu girinya ka ca nka sukarodunbana tɛ u la: Seginkanni kɛcogo sigilen dɔ ye GLP-1 nafa ni a lakanani jateminɛ mɔgɔ minnu fasalen don walima minnu girinya ka ca nka sukarodunbana tɛ ^la u Nin seginnkanni in ye kɛnɛyaso sɛgɛsɛgɛli caman jaabiw fara ɲɔgɔn kan, ka sinsin GLP-1 nɔ kan farikolo girinya dɔgɔyali la, farikoloɲɛnajɛ kɛcogoyaw la, ani kɛnɛyako bɛɛ lajɛlen na. Jateminɛw y’a jira ko GLP-1 bɛ tali kɛ farikolo girinya dɔgɔyaliba la ani ka ɲɛtaa jira kɛnɛya taamasiɲɛw la minnu bɛ tali kɛ fasa la, wa a bɛ se ka kɛ furakɛli fɛɛrɛ nafama ye fasa banabagatɔw bolo.

Banabagatɔ minnu tɛ sukarodunbana ye (dalilu minnu bɔra RCT caman na): Kɔrɔbɔli 4 kɔnɔ minnu kɛra ni mɔgɔw ye, banabagatɔ minnu farikolo girinya daminɛna ka se kilogaramu 96 ma ka se kilo 105 ma, olu ye GLP-1 miligaramu 2,4 pikiri kɛ u farikolo jukɔrɔ dɔgɔkun o dɔgɔkun ani ka ɲɛnamaya kɛcogo fɛɛrɛw (ladili, dumunikɛcogo ani farikoloɲɛnajɛ) kɛ walasa ka u farikolo girinya dɔgɔya. Kɔrɔbɔli dɔ kɛra banabagatɔw kan minnu tɛ sukarodunbanabagatɔw ye (N = 1961) o y’a jira ko dɔgɔkun 68 kɔfɛ, u girinya hakɛ cayalenba kɛra 15% (kg 15) ye, o ni jateminɛ siratigɛ la, danfaraba don ni 2% (kg 3) ye furakisɛ kulu la. Banabagatɔ minnu girinya dɔgɔyara ≥5%, olu hakɛ tun ye 86% ye ni i ye a suma ni 32% ye furakisɛ tabaga kulu la, ani hakɛ min ka kan ka furakɛ (NNT) = 2; banabagatɔ minnu girinya dɔgɔyara ≥10%, olu hakɛ tun ye 69% ye ni i ye a suma ni 12% ye pikirijikɛlan kulu la, ani NNT = 2. Kisɛ hakɛ dɔgɔyara dɔgɔkun 60 ɲɔgɔn na. Kɔnɔbara basigilen kɔlɔlɔw (AE) hakɛ tun ye 74% ye ni i ye a suma ni 48% ye furakisɛ kulu la, ani hakɛ min ka kan ka kɛ ka kojugu kɛ (NNH) = 3. Banabagatɔ minnu ye furakɛli dabila ka a sababu kɛ kɔlɔlɔw ye, olu hakɛ tun ye 7% ye ni i ye a suma ni 3% ye furakisɛ kulu la, ani NNH = 25. Kɔrɔbɔli wɛrɛ la min kɛra ni ɲɛnamaya kɛcogo gɛlɛn ye (N = 611), GLP-1 kulu la, girinya dɔgɔyali kɛra 16% (kg 17) ye, o ni jateminɛ siratigɛ la, a ni furakisɛ 6% (kg 6) tɛ kelen ye. Dose-exploration randomized controlled trial (N = 1210), banabagatɔw ye GLP-1 miligaramu 2,4 di dɔgɔkun o dɔgɔkun, GLP-1 miligaramu 1,0 dɔgɔkun o dɔgɔkun, walima furakisɛ. Dɔgɔkun 68 kɔfɛ, mɔgɔ girinya hakɛ cayalenba kɛra 10% (miligaramu 2,4), 7% (miligaramu 1,0) ani 3% (pikirijikɛlan) ye. Banabagatɔ minnu girinya dɔgɔyara ≥5%, olu hakɛ tun ye 69% (miligaramu 2,4), 57% (miligaramu 1,0) ye ni i ye a suma ni 29% ye furakisɛ kulu la. Ni miligaramu 2,4 ni miligaramu 1,0 ta kɛra, NNT = 9. A kɔlɔlɔw tun bɛ ɲɔgɔn ta hakɛ danfaralenw cɛ. Kisɛya sabatili sɛgɛsɛgɛli la min kɛra ni mɔgɔw ye (N = 803), mɔgɔ minnu tɛ sukarodunbanabagatɔ ye, olu ye dɔgɔkun o dɔgɔkun furakɛli kɛ ni GLP-1 miligaramu 2,4 ye dɔgɔkun 20 kɔnɔ, o kɔfɛ, u tilalen don k’u kɛ kulu ye min bɛ taa a fɛ GLP-1 furakɛli la walima furakisɛ kulu dɔ. Dɔgɔkun 48 kɔfɛ, kulu min bɛ taa a fɛ ka GLP-1 furakɛli kɛ, o ye u farikolo girinya 8% bɔ, ka sɔrɔ furakisɛ kulu min ye furakisɛ ta, o ye u farikolo girinya 7% bɔ.

Kuncɛli la, GLP-1 ye GLP-1 minɛbaga agoniste fura ye min nafa ka bon baara caman na. Sukarodunbana furakɛli siratigɛ la, a bɛ joli sukaro hakɛ kɔlɔsi ka ɲɛ ni a sirili ye GLP-1 sɔrɔyɔrɔw la, ka inisɔndiya bɔli sabati, ka sukaro bɔli bali, o bɛ furakɛli suguya nafama di sukarodunbana suguya 2 banabagatɔw ma. Fasa furakɛli fan fɛ, GLP-1 bɛ fanga sɔrɔli dɔgɔya kosɛbɛ fɛɛrɛw fɛ i n’a fɔ dumuni nege dabila cɛmancɛ la ani kɔnɔbara lankolonya bilali kɔfɛ, o bɛ fasa banabagatɔw dɛmɛ u ka u girinya dɔgɔya ani ka u ka farikoloɲɛnajɛ kɛcogo ɲɛ. Ka fara o kan, GLP-1 fana bɛ baarakɛcogo jira min bɛ se ka kɛ dusukun ni jolisiraw banaw kunbɛnni ni u furakɛli la. A ka dusukun ni jolisiraw ka faratiw ɲɛnabɔli bɛ fɛɛrɛ kura di walasa ka dusukun ni jolisiraw ka ko kɛtaw dɔgɔya.

A sɛbɛnbaga ko la

Fɛn minnu kofɔlen dòn san fɛ, olu bɛɛ ɲinini Kɛra, k’u Labɛn ani k’u Lajɛ Cocer Peptides fɛ.

Dɔnniya gafe sɛbɛnbaga

Hegner P ye ɲininikɛla ye Regensburg Iniwɛrisite la. A ka baara ɲɛsinnen bɛ Chimie, Cardiovasculaire System ani Cardiologie ma. Simi la, a bɛ waleyaw sɛgɛsɛgɛ minnu sirilen bɛ dusukun ni jolisiraw ka kɛnɛya la. Cardiovascular System kalanw na, a bɛ dusukun ni joli siraw baarakɛcogo sɛgɛsɛgɛ, ka furakɛli hakilinaw ɲini. A ka Dusukunnataw ɲininiw sinsinnen bɛ dusukunnabana kunbɛnni, a sɛgɛsɛgɛli ani a furakɛli kan.

Hegner ka dɛmɛw nafa ka bon kosɛbɛ. A ka kemikoro dɔnniyaw ye dusukun ni jolisiraw fura kura dilanni lawuli. A ka baara min kɛra dusukun ni joli siraw kɛcogo kan, o ye dɔ fara dusukun ni jolisiraw ka banaw faamuyali kan. Dɔgɔtɔrɔso siratigɛ la, a ka ɲininiw ye dusukunnabana furakɛli ɲɛ, ka banabagatɔw ladonni sariyaw kɔrɔta. Kuma bɛɛ la, Hegner ka fɛɛrɛ caman bɛ dusukun ni jolisiraw furakɛli nafa, ka jigiya di banaw doni dɔgɔyali ma ani banabagatɔw ka ɲɛtaa ɲuman. Hegner P tɔgɔ sɛbɛnnen bɛ citation (citation) ka ɲɛfɔli kɔnɔ ^[9]..

▎ Sɛbɛn minnu bɛ tali kɛ o la

[1] Memon A, Tehrim M, Kumari B. GLP-1: sɔgɔmada kura sukarodunbanabagatɔw ye[J]. Pakistan dɔgɔtɔrɔso jɛkulu ka gafe, 2023,73(3):721.DOI:10.47391/JPMA.7558.

[2] Ma H, Huang W, Wang X, ani mɔgɔ wɛrɛw. Jateminɛw sigicogo kan GLP-1R baarakɛcogo kan ni agoniste molekilɛri fitinin ye[J]. Selilɛri ɲinini, 2020,30(12):1140-1142.DOI:10.1038/s41422-020-0384-8.

[3] Kim HS, Jung C H. GLP-1 da la, Glucagon-like Peptide-1 Receptor Agonist fɔlɔ min bɛ dun: Yala a bɛ se ka kɛ marifa ye min bɛ se ka kɛ sukarodunbana suguya 2 ye wa?[J]. Duniya kɔnɔ, 2021,22(18).DOI:10.3390/ijms22189936.

[4] Gabery S, Salinas C. G., Paulsen S. J., ani mɔgɔ wɛrɛw. GLP-1 bɛ farikolo girinya dɔgɔya sosow la ni senfagabana siraw jɛnsɛnnenw ye[J]. Jci Hakilila, 2020,5(6).DOI:10.1172/jci.hakilila.133429.

[5] Katsurada K, Yada T. Pepitiri-1 min bɛ i n’a fɔ glucagon min bɛ sɔrɔ kɔnɔbara ni kunsɛmɛ na ani a minɛbaga agoniste ka farikoloɲɛnajɛ nɔw[J]. Jabɛtibana sɛgɛsɛgɛli gafe, 2016,7:64-69.DOI:10.1111/jdi.12464.

[6] Ryan D. H., Lingvay I, Colhoun H. M., ani a ɲɔgɔnnaw. GLP-1 nɔ minnu bɛ dusukun ni jolisiraw kɔlɔlɔw la mɔgɔ minnu girinya ka ca walima minnu fasalen don (SELECT) dalilu ni a dilanni[J]. Ameriki dusukunnakow gafe, 2020,229:61-69.DOI:10.1016/j.ahj.2020.07.008.

[7] Knudsen LB, Lau J. Liraglutide ni GLP-1 sɔrɔli ni u yiriwali[J]. Dancɛw ka ɲɛsin Endocrinologie ma, 2019,10.DOI:10.3389/fendo.2019.00155.

[8] Christou G. A., Katsiki N., Blundell J., ani a ɲɔgɔnnaw. GLP-1 ye fasa fura ye min bɛ layidu ta[J]. Fasa lajɛw, 2019,20(6):805-815.DOI:10.1111/obr.12839.

[9] Hegner P, Seitz S, Schopka S, ani a ɲɔgɔnnaw. GLP-1 bɛ sɔgɔsɔgɔninjɛ baara ɲɛ hadamadenw ka ɲɛgɛnɛsiraw la minnu bɛ yɔrɔ kelen na[J]. Erɔpu dusukunnakow gafe, 2024,45.DOI:10.1093/eurheartj/ehae666.3729.

[10] Ryan D. H., Lingvay I, Deanfield J., ani mɔgɔ wɛrɛw. GLP-1 ka farikolojidɛsɛ kuntaalajan nɔw fasa la ni sukarodunbana tɛ SELECT sɛgɛsɛgɛli la[J]. Sigida furakɛli, 2024,30(7):2049-2057.DOI:10.1038/s41591-024-02996-7.

[11] Alanazi M, Alshahrani J. A., Aljaberi A. S., ani mɔgɔ wɛrɛw. GLP-1 nɔ bɛ mɔgɔ minnu fasa walima minnu girinya ka ca ni sukarodunbana tɛ u la[J]. Cureus ka dɔgɔtɔrɔso dɔnniya gafe, 2024,16(8).DOI:10.7759/cureus.67889.

[12] Papakonstantinou I, Tsioufis K, Katsi V. GLP-1 ka baarakɛcogo ɲɛfɔli[J]. Sisan koɲɛw molekiyɔmu biologi la, 2024,46(12):14514-14541.DOI:10.3390/cimb46120872.

BƐƐRƐ KUNNAFONIW NI FƐRƐW KUNNAFONIW BƐƐ MIN BƐ NI WEBSITE KAN NA, olu BƐ KUNNAFONIW FƆLƆ DƆRƆN NI KALANSENW YE.  

Fɛn minnu bɛ di nin siti in kan, olu dabɔra ɲininiw dɔrɔn kama in vitro. Sɛgɛsɛgɛli in vitro (latinkan na: *glasi kɔnɔ*, o kɔrɔ ye gilasi kɔnɔ) bɛ kɛ hadamaden farikolo kɔkan. Nin fura ninnu tɛ furaw ye, Ameriki ka dumuniko ni furako ɲɛmɔgɔso (FDA) ma sɔn u ma, wa u man kan ka kɛ ka furakɛli bana, bana walima bana si bali, k’a furakɛ, walima k’a furakɛ. A dagalen don kosɛbɛ sariya fɛ ka nin fɛn ninnu don hadamaden walima bagan farikolo la cogo o cogo.